In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Did you know that your browser is out of date? To get the best experience using our website we recommend that you upgrade to a newer version. Learn more.

We use cookies to optimise the design of this website and make continuous improvement. By continuing your visit, you consent to the use of cookies. Learn more

ESC statement in response to the FDA determination that trans fatty acids are no longer considered safe for consumption

The European Society of Cardiology welcomes FDA decision to ban industrial trans fats

The American Food and Drug Administration (FDA) considers trans fatty acids (TFA) unsafe for consumption.

Health Policy & Healthcare Settings


Sophia Antipolis, 06 July 2015: The American Food and Drug Administration (FDA) considers trans fatty acids (TFA) unsafe for consumption. The FDA is providing a three-year compliance period to allow industry to gradually phase out their use in processed food. This step is expected to reduce cardiovascular disease and prevent thousands of fatal heart attacks every year in the US.  

The European Society of Cardiology welcomes the FDA decision "to remove artificial trans fat from the food supply" (1) and calls upon European policy makers to urgently bring forward EU-wide regulation to address this important health issue.

TFAs are widely recognized as the most harmful fat with regard to causing cardiovascular disease (CVD). Partially hydrogenated oils are the major source of artificial transfats in the food supply. They are the most often used source of fat in commercial bakery products. TFAs raise the level of LDL (“bad”) cholesterol in the blood. An elevated LDL cholesterol level in the blood increases the risk of developing heart disease. The detrimental effects of TFAs on heart health and mortality are now beyond dispute (2,3).

Cardiovascular disease (CVD) is the main cause of death in Europe. Each year CVD causes over 4 million deaths in Europe and over 1.9 million deaths in the EU.  CVD causes 47% of all deaths in Europe and 40% of deaths in the EU (4). There are very significant differences in mortality rates between countries. The current TFA intake in Eastern and South Eastern Europe is often high, increasing the European CVD burden and widening national and international inequalities.

Based on the effects on cardiovascular health of TFA intake; the positive experiences from different interventions to limit TFA intake and the accumulated knowledge on differential consumption of TFAs across Europe, the European Society of Cardiology believes that a regulatory intervention is necessary to ensure that all EU citizens can effectively reduce their TFA intake

For the full European Society of Cardiology position on trans fatty acids, please refer to our 2014 paper on Industrial Trans Fatty Acids (5). The European Chronic Disease Alliance (of which the European Society of Cardiology is part) has also issued a policy document (6).

Ends

References

1)    FDA Announcement see here
2)    Brouwer et al, Eur J Clin Nutr 2013 see here
3)    Kiage et al, Am J Clin Nutr 2013 see here
4)    CVD Statistics see here
5)    ESC Position Paper on Industrial Trans Fatty Acids (2014) see here
6)    European Chronic Disease Alliance position on the need for EU regulation to set upper limits for industrially produced transfats (2015) see here

Notes to editor

About the European Society of Cardiology
The European Society of Cardiology (ESC) represents more than 90 000 cardiology professionals across Europe and the Mediterranean. Its mission is to reduce the burden of cardiovascular disease in Europe.